Skip to Main Content

Try STAT+ TODAY

D.C. Diagnosis

STAT’s D.C. Diagnosis newsletter is an insider’s guide to the politics and policy of health and medicine, delivered to your inbox on Tuesdays and Thursdays. Sign up here.

Most Read

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

D.C. Diagnosis Nicholas Florko

What happened to the FDA’s toughest regulator?

D.C. Diagnosis Nicholas Florko

As Congress takes up FDA oversight of dietary supplements, a lobbying showdown looms

D.C. Diagnosis Rachel Cohrs

AstraZeneca’s ambitious vaccine dreams are finally, officially dead

D.C. Diagnosis Nicholas Florko

Operation Warp Speed — now, the ‘CAG’— is here to stay

D.C. Diagnosis Nicholas Florko

Which drug maker spent the most on lobbying this summer? The answer will surprise you

D.C. Diagnosis Nicholas Florko

Pharma showers John Thune with campaign cash

D.C. Diagnosis Nicholas Florko

Biogen’s head-scratching new lobbyist hire

All Coverage

D.C. Diagnosis Rachel Cohrs

It’s not looking good for Covid and monkeypox funding, problems ahead for PrEP, & the not-so-historic Juul settlement

D.C. Diagnosis Elissa Welle

Democrats’ TGIF moment, pathologists defend their turf, & Biogen’s back at the FDA’s doorstep

advertisement

D.C. Diagnosis Edward Chen

A chaotic sprint to lower insulin prices and AIDS activists go after Biden on monkeypox

D.C. Diagnosis Rachel Cohrs

The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill

D.C. Diagnosis Nicholas Florko

PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama

D.C. Diagnosis Rachel Cohrs

The unlikely crusader who’s winning the fight to lower hospital prices

D.C. Diagnosis Lev Facher

The Senate health committee finally marks up its user fee bill

D.C. Diagnosis Rachel Cohrs

California senators advance three bills meant to crack down on health insurers

D.C. Diagnosis Nicholas Florko

A no good, very bad week for the FDA

D.C. Diagnosis Nicholas Florko

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

D.C. Diagnosis Nicholas Florko

The FDA’s ban on menthol in cigarettes clears a major regulatory hurdle

D.C. Diagnosis Nicholas Florko

The next battle in the never-ending war over Aduhelm

D.C. Diagnosis Nicholas Florko

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

D.C. Diagnosis Nicholas Florko

Inside the push for a permanent pandemic preparedness office at the White House

D.C. Diagnosis Nicholas Florko

Covid budget crunch looms over government funding fight

D.C. Diagnosis Nicholas Florko

The FDA’s promised menthol ban is about to face a critical test

D.C. Diagnosis Nicholas Florko

Is the Senate gearing up to actually pass drug pricing legislation?

D.C. Diagnosis Nicholas Florko

The new lightning rod in the fight over high drug prices

D.C. Diagnosis Nicholas Florko

A no good, very bad week for Biden’s science agenda

D.C. Diagnosis Nicholas Florko

Democrats aren’t ready to support Biden’s FDA pick, Robert Califf

D.C. Diagnosis Nicholas Florko

What does the Build Back Better Act actually mean for the health care industry?

D.C. Diagnosis Nicholas Florko

Scott Gottlieb: Trump’s shadow FDA commissioner during Covid-19?

D.C. Diagnosis Nicholas Florko

Congress is ready to dig into drug prices

D.C. Diagnosis Nicholas Florko

Biden wants a drug pricing plan in 45 days. Who’s going to write it?

D.C. Diagnosis Nicholas Florko

Are pharma mergers bad for biotech?